Pharma Intelligence is part of the Business Intelligence Division of Informa PLC
This is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
9 Total results for product and free and sample content found
Pink Sheet
By Francesca Bruce 07 Jun 2017
The clinical potential of immuno-oncology drugs does not seem to be reflected in approaches by health technology assessment bodies, with different interpretations of data.
Topic immuno-oncology
Scrip
By Joseph Haas 13 Feb 2017
New cancer immunotherapies are doing well in lung cancer, with Merck's Keytruda picking up share in the first-line setting and Roche's Tecentriq in second-line. Bristol-Myers Squibb is banking on combo therapy to restore its momentum.
Topic immuno-oncology
Scrip
By Emily Hayes 03 Feb 2017
Merck's filings in bladder cancer span first-line and second-line treatment and include overall survival data. Roche also is getting ready to move Tecentriq to the frontline setting.
Scrip
By Eleanor Malone 12 Dec 2016
Delivering clinical advances in areas including immuno-oncology and Alzheimer's disease data while navigating the stormy seas of global politics could represent an opportunity for pharma to influence change. An uptick in sector M&A could also ensue if Trump offers US corporations a tax holiday.
Topic immuno-oncology
Datamonitor Healthcare
By Colin White, Robert Jeng & Jolene Lau 26 Oct 2016
This is an overview of the field of immuno-oncology and the various immuno-oncology classes. Immuno-oncology is one of the most promising and fastest growing areas of cancer research, as well
Topic immuno-oncology
Scrip
By Jessica Merril 10 Oct 2016
Merck’s strong Phase II data testing Keytruda with chemotherapy
Topic immuno-oncology
Topic immuno-oncology
Datamonitor Healthcare
14 Sep 2015
Entering an established market as a new player can be daunting. Often it's difficult to know exactly where you should be targeting your trial, and also what patient group you should be targeting your treatment at.
Topic immuno-oncology
Pharmaprojects
By Jonathan Stephens 06 Jul 2015
Since its inception in the mid-20th century, chemotherapy has been the mainstay of cancer treatment and has become increasingly specific and effective.
Topic immuno-oncology
No Records Found
Request a live demo
Getting a demo tailored to your needs is the best way to see how our solutions will help you gain an advantage.
Request live demo now:
How can we help you?
Our team is always happy to hear from you. Please call us at:
Report store
Have an immediate and specific information need?
Browse and buy from 1000s of analysis and research reports now:
